The Next Wave of CAR T Innovation for RRMM: Insights Into Emerging GPRC5D-Directed CAR T-Cell Therapies

Please visit answersincme.com/KTB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Krina Patel, MD, MSc. In this activity, Krina Patel, MD, MSc, an expert in multiple myeloma, discusses emerging GPRC5D CAR T-cell therapies in relapse/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Describe the clinical rationale for the use of emerging GPRC5D CAR T-cell therapy in the context of the current treatment landscape for relapsed/refractory multiple myeloma (RRMM); Review the implications of the latest clinical evidence for emerging GPRC5D CAR T-cell therapy in the treatment of patients with RRMM; and Outline potential considerations to optimally integrate GPRC5D CAR T-cell therapies, as they become available, into treatment plans for patients with RRMM.